Loading...
XHKG2216
Market cap40mUSD
Dec 23, Last price  
0.59HKD
1D
3.51%
1Q
20.41%
IPO
-95.99%
Name

Broncus Holding Corp

Chart & Performance

D1W1MN
XHKG:2216 chart
P/E
P/S
3.90
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
10m
+8.95%
8,072,0003,259,00010,891,0009,413,00010,255,000
Net income
-28m
L+0.20%
-32,551,000-48,786,000-236,178,000-28,036,000-28,091,000
CFO
-26m
L-15.58%
-15,815,000-15,588,000-31,494,000-30,954,000-26,132,000
Earnings
May 20, 2025

Profile

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.
IPO date
Sep 24, 2021
Employees
314
Domiciled in
CN
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
10,255
8.95%
9,413
-13.57%
10,891
234.18%
Cost of revenue
43,597
41,683
50,160
Unusual Expense (Income)
NOPBT
(33,342)
(32,270)
(39,269)
NOPBT Margin
Operating Taxes
3
3
3
Tax Rate
NOPAT
(33,345)
(32,273)
(39,272)
Net income
(28,091)
0.20%
(28,036)
-88.13%
(236,178)
384.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
55
119
214,899
BB yield
-0.01%
-0.01%
-8.92%
Debt
Debt current
1,131
681
752
Long-term debt
3,563
2,232
3,131
Deferred revenue
53
102
28
Other long-term liabilities
175
200
Net debt
(88,223)
(111,446)
(223,324)
Cash flow
Cash from operating activities
(26,132)
(30,954)
(31,494)
CAPEX
(664)
(856)
(1,881)
Cash from investing activities
5,486
(87,569)
(1,753)
Cash from financing activities
(1,459)
(572)
241,822
FCF
(33,930)
(37,926)
(41,059)
Balance
Cash
156,884
187,909
227,207
Long term investments
(63,967)
(73,550)
Excess cash
92,404
113,888
226,662
Stockholders' equity
(461,887)
(379,976)
(349,601)
Invested Capital
649,665
594,861
594,090
ROIC
ROCE
EV
Common stock shares outstanding
488,571
487,749
298,960
Price
0.79
-65.50%
2.29
-71.59%
8.06
 
Market cap
385,971
-65.44%
1,116,946
-53.65%
2,409,621
 
EV
297,747
1,005,500
2,186,297
EBITDA
(30,476)
(29,422)
(36,578)
EV/EBITDA
Interest
163
98
170
Interest/NOPBT